Ticker

Vancouver, British Columbia – TheNewswire - August 17, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPC F ” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company developing novel therapies for difficult-to-treat cancers , today announced the appointment of Markus Loeffler, MD, MBA as Chief Medical Officer (CMO) of the Company.   Dr. Loeffler's appointment comes as Helix…

Vancouver, British Columbia; August 14, 2026 – TheNewswire - Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company developing novel therapies for difficult-to-treat cancers , today announced changes to its Board of Directors (the “Board” ), effective immediately.   Mr. Janusz Grabski has resigned from Helix's Board, with immediate…

Vancouver, British Columbia – TheNewswire - June 30 , 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced the appointments of Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations . The…

Vancouver, British Columbia – TheNewswire - June 12, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today reported financial results and the filing of the Company's unaudited interim financial statements as of and for the three- and nine-month…